

## II. AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in the application:

1. (Canceled)

2. (Currently Amended) A method according to claim 29, wherein said delivering comprises:

providing an occlusive body which comprises the cannabinoid composition; and  
positioning the occlusive body on the subject's skin under conditions effective to transdermally deliver the selected cannabinoid composition to the subject's skin.

3. (Currently Amended) A method according to claim 2, wherein the occlusive body further comprises:

an impermeable backing; and  
a rate-controlling microporous membrane, wherein the backing and membrane define a cavity therebetween and wherein the selected cannabinoid composition is disposed within the cavity.

4. (Currently Amended) A method according to claim 3, wherein the selected occlusive body further comprises:

a viscous flowable gel disposed within the cavity, wherein the viscous flowable gel immobilizes the cannabinoid composition within the cavity.

5. (Original) A method according to claim 3, wherein the occlusive body further comprises:  
an adhesive for attaching the occlusive body to skin.

6. (Previously Presented) A method according to claim 29, wherein the illness is selected from the group consisting of AIDS and cancer.

7. (Canceled)

8. (Currently Amended) A method according to claim 29, wherein the selected cannabinoid composition is delivered via a topical formulation.

9. (Currently Amended) A method according to claim 29, wherein the selected cannabinoid composition is delivered via a patch.

10. (Currently Amended) A method according to claim 29, further comprising the steps of:  
providing an opiate; and  
delivering the opiate transdermally with the cannabinoid composition to the subject.

11-28. (Canceled)

29. (Previously Presented) A method for relieving symptoms associated with illness or discomfort associated with the treatment of illness in a mammalian subject, said method comprising:

providing a cannabinoid composition consisting essentially of cannabidiol; and  
delivering the cannabinoid composition transdermally to the subject.

30. (Previously Presented) The method of claim 29 wherein the subject is selected from the group consisting of patients experiencing a loss of appetite, patients experiencing chronic pain, patients experiencing spasticity, patients experiencing dystonia, and patients experiencing nausea and vomiting.